首页> 外文期刊>Expert opinion on biological therapy >Emerging biologic therapies for hypercholesterolaemia
【24h】

Emerging biologic therapies for hypercholesterolaemia

机译:新兴的高胆固醇血症生物疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: LDL-cholesterol (LDL-C) is one of the most well-established risk factors for CV disease. Indeed, therapies that decrease LDL-C are proven to effectively reduce the risk of atherosclerotic CV disease. Monoclonal antibodies (mAbs) that target proprotein convertase subtilisin/kexin type 9 (PCSK9) have recently gained traction as a promising therapeutic strategy.Areas covered: In this review, the authors discuss the effectiveness of mAbs against PCSK9 in lowering low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipid fractions. The discontinuation in the development of bococizumab due to efficacy and safety concerns, and the initial promising data about inclisiran, a long-acting small inhibiting RNA molecule against PCSK9 synthesis, is also discussed.Expert opinion: Initial data about cardiovascular (CV) outcomes in large scale, long-term studies suggest a possible further therapeutic pathway for LDL-C reduction, and currently support the notion that further LDL-C reduction, obtained with PCSK9 inhibition on top of best available therapy, provides increased CV protection in subjects at very high CV risk. The development and marketing of mAbs against PCSK9 could help to redefine current therapeutic strategies aimed at reducing cardiovascular (CV) morbidity and risk, through the reduction of LDL-C concentrations. The cost-effectiveness of these emerging drugs is yet to be established.
机译:简介:LDL-胆固醇(LDL-C)是CV病的最熟悉的危险因素之一。实际上,证明了降低LDL-C的疗法,以有效降低动脉粥样硬化CV疾病的风险。靶素蛋白转化酶枯草杆菌蛋白酶/ kexin型(PCSK9)的单克隆抗体(MAB)最近获得了牵引力作为有前途的治疗策略。涵盖:在本综述中,作者讨论了MAB对PCSK9降低低密度脂蛋白胆固醇的有效性(LDL-C)和其他致动血液脂质级分。还讨论了由于疗效和安全问题导致的Bococizumab的开发,以及关于增容的初始有前途的数据,这是针对PCSK9合成的长效的小抑制RNA分子,是关于CARK9合成的长效的小抑制RNA分子.Expert意见:关于心血管(CV)结果的初始数据大规模,长期研究表明,即LDL-C还原的可能进一步的治疗途径,目前支持进一步的LDL-C还原的观念,在最佳可用治疗上获得PCSK9抑制,在非常受试者中提供了增加的CV保护。高CV风险。 MAB对PCSK9的开发和销售有助于通过减少LDL-C浓度来重新定义目前的治疗策略,旨在减少心血管(CV)发病率和风险。这些新兴药物的成本效益尚未建立。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号